Circulating VEGF levels as a biomarker to clinical benefit to PTC299, the first inhibitor of VEGF synthesis Meeting Abstract
| Authors: | George, C. P.; Luke, J. J.; Winkelman, J.; Cao, Y. T. K. H.; Shakes, L.; Donnelly, K.; Darby, C. H.; Davis, T. W.; Elfring, G. L.; Schwartz, G. K. |
| Abstract Title: | Circulating VEGF levels as a biomarker to clinical benefit to PTC299, the first inhibitor of VEGF synthesis |
| Meeting Title: | 48th Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 30 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2012 Jun 1-5 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2012-05-20 |
| Language: | English |
| ACCESSION: | WOS:000318009802279 |
| PROVIDER: | wos |
| DOI: | 10.1200/jco.2012.30.15_suppl.e13588 |
| Notes: | Meeting Abstract: e13588 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
-
385Schwartz -
12Luke -
12
Winkelmann -
2
Cao -
1
Shakes
Related MSK Work